These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 12506023)
1. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Sansonno D; De Re V; Lauletta G; Tucci FA; Boiocchi M; Dammacco F Blood; 2003 May; 101(10):3818-26. PubMed ID: 12506023 [TBL] [Abstract][Full Text] [Related]
2. B-cell depletion in the treatment of mixed cryoglobulinemia. Sansonno D; Tucci FA; Montrone M; Troiani L; Sansonno L; Gatti P; Lauletta G Dig Liver Dis; 2007 Sep; 39 Suppl 1():S116-21. PubMed ID: 17936212 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Petrarca A; Rigacci L; Caini P; Colagrande S; Romagnoli P; Vizzutti F; Arena U; Giannini C; Monti M; Montalto P; Matucci-Cerinic M; Bosi A; Laffi G; Zignego AL Blood; 2010 Jul; 116(3):335-42. PubMed ID: 20308604 [TBL] [Abstract][Full Text] [Related]
4. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Cacoub P; Delluc A; Saadoun D; Landau DA; Sene D Ann Rheum Dis; 2008 Mar; 67(3):283-7. PubMed ID: 17644544 [TBL] [Abstract][Full Text] [Related]
5. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Roccatello D; Baldovino S; Rossi D; Mansouri M; Naretto C; Gennaro M; Cavallo R; Alpa M; Costanzo P; Giachino O; Mazzucco G; Sena LM Nephrol Dial Transplant; 2004 Dec; 19(12):3054-61. PubMed ID: 15494358 [TBL] [Abstract][Full Text] [Related]
6. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Dammacco F; Tucci FA; Lauletta G; Gatti P; De Re V; Conteduca V; Sansonno S; Russi S; Mariggiò MA; Chironna M; Sansonno D Blood; 2010 Jul; 116(3):343-53. PubMed ID: 20308602 [TBL] [Abstract][Full Text] [Related]
7. Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. Petrarca A; Rigacci L; Monti M; Giannini C; Bernardi F; Caini P; Colagrande S; Bosi A; Laffi G; Zignego AL Dig Liver Dis; 2007 Sep; 39 Suppl 1():S129-33. PubMed ID: 17936214 [TBL] [Abstract][Full Text] [Related]
8. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Saadoun D; Resche Rigon M; Sene D; Terrier B; Karras A; Perard L; Schoindre Y; Coppéré B; Blanc F; Musset L; Piette JC; Rosenzwajg M; Cacoub P Blood; 2010 Jul; 116(3):326-34; quiz 504-5. PubMed ID: 20439619 [TBL] [Abstract][Full Text] [Related]
9. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Saadoun D; Resche-Rigon M; Sene D; Perard L; Karras A; Cacoub P Ann Rheum Dis; 2008 Oct; 67(10):1431-6. PubMed ID: 18178690 [TBL] [Abstract][Full Text] [Related]
10. Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. Stasi C; Triboli E; Arena U; Urraro T; Petrarca A; Gragnani L; Laffi G; Zignego AL J Transl Med; 2014 Jan; 12():21. PubMed ID: 24456582 [TBL] [Abstract][Full Text] [Related]
11. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Roccatello D; Baldovino S; Rossi D; Giachino O; Mansouri M; Naretto C; Di Simone D; Francica S; Cavallo R; Alpa M; Napoli F; Sena LM Clin Rev Allergy Immunol; 2008 Feb; 34(1):111-7. PubMed ID: 18270864 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Zaja F; De Vita S; Mazzaro C; Sacco S; Damiani D; De Marchi G; Michelutti A; Baccarani M; Fanin R; Ferraccioli G Blood; 2003 May; 101(10):3827-34. PubMed ID: 12560225 [TBL] [Abstract][Full Text] [Related]
17. Acute wrist and foot drop associated with hepatitis C virus related mixed cryoglobulinemia: rapid response to treatment with rituximab. Uppal R; Charles E; Lake-Bakaar G J Clin Virol; 2010 Jan; 47(1):69-71. PubMed ID: 19892591 [TBL] [Abstract][Full Text] [Related]
18. B cell activating factor (BAFF) in the natural history of chronic hepatitis C virus liver disease and mixed cryoglobulinaemia. Lake-Bakaar G; Jacobson I; Talal A Clin Exp Immunol; 2012 Nov; 170(2):231-7. PubMed ID: 23039894 [TBL] [Abstract][Full Text] [Related]
19. Long-term remission with rituximab in a patient with severe hepatitis C virus-induced mixed cryoglobulinemia. Fortea-Ormaechea JI; Lozano-Maya M; Adán-Merino L; Barrio-Antoranz J; Martín-Chavarri S; Corchete-Prats E; Martínez-Acebes E; Aldeguer-Martínez M Rev Esp Enferm Dig; 2013 Sep; 105(8):490-3. PubMed ID: 24274448 [TBL] [Abstract][Full Text] [Related]
20. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Ferri C; Cacoub P; Mazzaro C; Roccatello D; Scaini P; Sebastiani M; Tavoni A; Zignego AL; De Vita S Autoimmun Rev; 2011 Nov; 11(1):48-55. PubMed ID: 21821153 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]